• Something wrong with this record ?

Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents

J. Fucikova, L. Palova-Jelinkova, V. Klapp, P. Holicek, T. Lanickova, L. Kasikova, J. Drozenova, D. Cibula, B. Álvarez-Abril, E. García-Martínez, R. Spisek, L. Galluzzi

. 2022 ; 8 (5) : 426-444. [pub] 20220216

Language English Country United States

Document type Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018671

At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018671
003      
CZ-PrNML
005      
20220804134946.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.trecan.2022.01.010 $2 doi
035    __
$a (PubMed)35181272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fucikova, Jitka $u Sotio, Prague, Czech Republic; Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Electronic address: fucikova@sotio.com
245    10
$a Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents / $c J. Fucikova, L. Palova-Jelinkova, V. Klapp, P. Holicek, T. Lanickova, L. Kasikova, J. Drozenova, D. Cibula, B. Álvarez-Abril, E. García-Martínez, R. Spisek, L. Galluzzi
520    9_
$a At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
650    12
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $7 D000077216
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunomodulace $7 D056747
650    12
$a nádory vaječníků $x farmakoterapie $7 D010051
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palova-Jelinkova, Lenka $u Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Klapp, Vanessa $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
700    1_
$a Holicek, Peter $u Sotio, Prague, Czech Republic; Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Lanickova, Tereza $u Sotio, Prague, Czech Republic; Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Kasikova, Lenka $u Sotio, Prague, Czech Republic
700    1_
$a Drozenova, Jana $u Department of Pathology, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Álvarez-Abril, Beatriz $u Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain
700    1_
$a García-Martínez, Elena $u Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain; Universidad Católica San Antonio de Murcia, Guadalupe, Spain
700    1_
$a Spisek, Radek $u Sotio, Prague, Czech Republic; Department of Immunology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Centre, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. Electronic address: deadoc80@gmail.com
773    0_
$w MED00195479 $t Trends in cancer $x 2405-8025 $g Roč. 8, č. 5 (2022), s. 426-444
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35181272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134939 $b ABA008
999    __
$a ok $b bmc $g 1822341 $s 1169914
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 8 $c 5 $d 426-444 $e 20220216 $i 2405-8025 $m Trends in cancer $n Trends Cancer $x MED00195479
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options